The Inscripta® Blog
April 18, 2022
Highlights from the 2022 Built With Biology conference
After two-and-a-half years, the synthetic biology industry gathered again in person at the Built With Biology Global Synthetic Biology…
February 8, 2022
"Digital Genome Engineering: Unlocking the Potential of Synthetic Biology" Symposium Highlights
Inscripta partnered with Build With Biology to put on a half-day virtual symposium “Digital Genome Engineering: Unlocking the Potential of…
January 25, 2022
JP Morgan 2022: The Promise of Synthetic Biology
The healthcare industry kicks off each new year not when the ball drops in Times Square but with the start of the annual JP Morgan Healthcare…
January 11, 2022
What Makes CRISPR Like a Movie Star? SynBioBeta podcast with Nandini Krishnamurthy
Nandini Krishnamurthy, Inscripta’s VP of Microbial Business, appeared as a guest on SynBioBeta’s Built with Biology podcast. The new podcast…
December 14, 2021
New Market Report Finds Near-Boundless Opportunity in Synthetic Biology
A new U.S. thematic market report from Barclays’ Equity Research team shines a spotlight on the tremendous potential in the Synthetic Biology…
November 23, 2021
Recap of SynBioBeta’s Chemicals & Materials Digital Conference
As we excitedly await the January 2022 in-person SynBioBeta Conference, the synbio community organizers are keeping the conversation alive…
October 26, 2021
Podcast: Why Genome Engineering Is Important for Amyris R&D
In a new podcast, Mendelspod host Theral Timpson interviewed Kirsten Benjamin, the vice president of R&D at Amyris.
October 14, 2021
Perspective: 40 Years of Biotech
Genetic Engineering and Biotechnology News (GEN), a pioneering publication covering various biotech topics, is celebrating its 40th anniversary…
October 5, 2021
Amyris Adopts the Onyx™ Platform to Enhance Development of Sustainable Ingredients
We are excited to bring our game-changing technology to the hands of great scientists. Today, we announced that the Onyx platform has been…